Delivery of apoptotic signal to rolling cancer cells: A novel biomimetic technique using immobilized TRAIL and E‐selectin

The survival rate for patients with metastases versus localized cancer is dramatically reduced, with most deaths being associated with the formation of secondary tumors. Circulating cancer cells interact with the endothelial lining of the vasculature via a series of adhesive interactions that facilitate tethering and firm adhesion of cancer cells in the initial steps of metastasis. TNF‐related apoptosis‐inducing ligand (TRAIL) holds promise as a tumor‐specific cancer therapeutic, by inducing a death signal by apoptosis via the caspase pathway. In this study, we exploit this phenomenon to deliver a receptor‐mediated apoptosis signal to leukemic cells adhesively rolling along a TRAIL and selectin‐bearing surface. Results show that cancer cells exhibit selectin‐mediated rolling in capillary flow chambers, and that the rolling velocities can be controlled by varying the selectin and selectin surface density and the applied shear stress. It was determined that a 1 h rolling exposure to a functionalized TRAIL and E‐selectin surface was sufficient to kill 30% of captured cells compared to static conditions in which 4 h exposure was necessary to kill 30% of the cells. Thus, we conclude that rolling delivery is more effective than static exposure to a TRAIL immobilized surface. We have also verified that there is no significant effect of TRAIL on hematopoietic stem cells and other normal blood cells. This represents the first demonstration of a novel biomimetic method to capture metastatic cells from circulation and deliver an apoptotic signal. Biotechnol. Bioeng. 2009;102: 1692–1702. © 2008 Wiley Periodicals, Inc.

[1]  F. Orr,et al.  Tumor cell interactions with the microvasculature: a rate-limiting step in metastasis. , 2001, Surgical oncology clinics of North America.

[2]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[3]  A. Evdokiou,et al.  Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy , 2003, British Journal of Cancer.

[4]  R. Khokha,et al.  Steps in tumor metastasis: new concepts from intravital videomicroscopy , 1995, Cancer and Metastasis Reviews.

[5]  M. Nau,et al.  Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. , 2001, Gynecologic oncology.

[6]  I. Macdonald,et al.  Cancer spread and micrometastasis development: Quantitative approaches for in vivo models , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[7]  M. Clarke,et al.  Identification of pancreatic cancer stem cells. , 2007, Cancer research.

[8]  D. Nance,et al.  Interactions between cancer cells and the endothelium in metastasis , 2000, The Journal of pathology.

[9]  G. Naumov,et al.  Molecular biology of breast cancer metastasis: Clinical implications of experimental studies on metastatic inefficiency , 2000, Breast Cancer Research.

[10]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[11]  C. Pona,et al.  Effectiveness of Leukocyte Filters in Reducing Tumor Cell Contamination after Intraoperative Blood Salvage in Lung Cancer Patients , 1997, Vox sanguinis.

[12]  R. Waugh,et al.  Thermoelasticity of red blood cell membrane. , 1979, Biophysical journal.

[13]  I. Bechmann,et al.  Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.

[14]  J. Jelinek,et al.  TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors , 2002, Leukemia.

[15]  E. McCulloch,et al.  Mouse myeloma tumor stem cells: a primary cell culture assay. , 1971, Journal of the National Cancer Institute.

[16]  A. Varki,et al.  Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. , 1999, The American journal of pathology.

[17]  N. Mitsiades,et al.  Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. , 2001, Cancer research.

[18]  J. Fricker On the TRAIL to a new cancer therapy. , 1999, Molecular medicine today.

[19]  D. Hammer,et al.  Lu‐ECAM‐1‐mediated adhesion of melanoma cells to endothelium under conditions of flow , 1996, International journal of cancer.

[20]  B. Bonavida,et al.  A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. , 2002, Advances in cancer research.

[21]  G. Naumov,et al.  Critical steps in hematogenous metastasis: an overview. , 2001, Surgical oncology clinics of North America.

[22]  L. Andĕra,et al.  Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo , 2007, British Journal of Cancer.

[23]  E. Alnemri,et al.  TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. , 2000, Blood.

[24]  D. Gilliland,et al.  Leukaemia stem cells and the evolution of cancer-stem-cell research , 2005, Nature Reviews Cancer.

[25]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[26]  K. Schulze-Osthoff,et al.  Potential and caveats of TRAIL in cancer therapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  R. Yu,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. , 2000, Cancer research.

[28]  T. Miki,et al.  Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. , 2001, The Journal of urology.

[29]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[30]  Y. Gazitt TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells , 1999, Leukemia.

[31]  J. Liesveld,et al.  Investigating the Feasibility of Stem Cell Enrichment Mediated by Immobilized Selectins , 2007, Biotechnology progress.

[32]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[33]  M. L. Blair,et al.  Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device , 2008, British journal of haematology.

[34]  K. Oldhafer,et al.  Filtration of malignant cells: tumour cell depletion in an ex vivo model using a leukocyte adhesion filter , 2001, Perfusion.

[35]  I. Sarelius,et al.  Preferential Binding of Leukocytes to the Endothelial Junction Region in Venules In Situ , 2005, Microcirculation.

[36]  A. Belldegrun,et al.  Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis , 2001, Journal of immunotherapy.

[37]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[38]  M. Edelman,et al.  The potential for reintroduction of tumor cells during intraoperative blood salvage: reduction of risk with use of the RC-400 leukocyte depletion filter. , 1996, Urology.

[39]  J. Liesveld,et al.  P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow. , 2008, Clinical chemistry.

[40]  E. Bröcker,et al.  Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.